Synergism of DolCas Biotech BCM-95 Components Confirmed for Colitis

A new study shows that BCM-95®, a patented turmeric extract, is significantly more effective than standard curcumin for reducing the disease activity and inflammatory burdens of colitis.

     (Photo: http://mma.prnewswire.com/media/513565/DolCas_Biotech.jpg )

The study, by Shusuke Toden, Ph.D., et alia, of Baylor University, Dallas, Texas, published April, 2017, in the journal Scientific Reports, compared the bioactivity of two curcumin products, standardized 95% curcumin and BCM-95, in an imposed animal model of colitis. BCM-95 combines at least 86% pure curcuminoids with essential oils from turmeric, and is patented for a specific 45% content of ar-turmerones within the essential oil blend.

In the study, groups were pretreated with standard curcumin or BCM-95 at 5 mg, 25 mg or 50 mg/kg over one week. The standard curcumin/BCM-95 groups were continued in tandem with the 1-week 3% dextran sulfate sodium (DSS) regimen to induce colitis, then compared to the untreated group. From the induction of colitis, disease severity was evaluated daily using the disease activity index (DAI).

Changes in colon length, body weight, stool consistency and visible blood in the feces were assessed. Gene expression panels for inflammatory markers were also evaluated. BCM-95-but not standard curcumin-attenuated disease changes more significantly per the DAI (p < 0.001), with the progression of the disease (i.e. day 5 vs. day 7), and with increasing dose (25 mg vs. 50 mg/kg). Moreover, colon-shortening was lessened by the BCM-95 group, whereas no change was observed in the standard curcumin group.

The BCM-95 group also modulated significantly more inflammatory genes than did the curcumin group. The most significant changes for the BCM-95 group, as associated with colon inflammation and disease progression, were the up-regulation of anti-inflammatory markers IL-10 and IL-11. These markers were not significantly affected in the standard curcumin group.

In another experiment, a stand-alone ar-turmerone-enriched essential oil (ETO) group was compared to the untreated DSS control group, the standard curcumin group, and the BCM-95 group to evaluate ETO's impact on disease activity scores. The BCM-95 group proved ETO to be more beneficial than for all other groups, strongly suggesting that synergism is at play in the enhanced bioactivity results. The specific content of essential oil-derived sesquiterpenes, known as ar-turmerones, at a 45% ratio of the oils, complements the 86% content of curcumin in making BCM-95 novel.

"Of all the non-curcumin constituents evaluated thus far, such aromatic turmerones have been regarded as the most favorable in complementing the anti-inflammatory and antioxidant action of curcumin," says Shavon Jackson-Michel, ND, Medical and Scientific Affairs Advisor for DolCas Biotech. "The enhanced benefit realized by the combination of ar-turmerone enhanced essential oils with curcumin, as uniquely found in BCM-95, suggests that, while ETO does not offer significant benefit on its own, it adds to the anti-inflammatory profile of curcumin."

DolCas Biotech, LLC, owns the worldwide brand rights of BCM-95 in a joint venture with India-based manufacturer, Arjuna Naturals Extracts, Ltd. With full oversight of BCM-95's entire supply chain, a 14-year history of safe use, and GRAS status (as affirmed by a panel of experts), DolCas and Arjuna offer the industry a pure, clean, and safe raw material.

The two companies have diligently collaborated with renowned researchers, domestically and internationally, to additionally establish BCM-95 as a clinically studied, science-backed ingredient. BCM-95 has been awarded 12 patents and consistently makes headlines with cutting-edge research, such as this colitis study. "The confirmation of synergism provides partners-for example Europharma and Life Extension-a significant advantage in marketing their BCM-95 based formulas as verified for bioavailability and enhanced bioactivity," adds Jackson-Michel.

For more information, contact:
Company contact
DolCas Biotech, LLC
Mr. Nipen Lavingia
VP of Business Development
Tell: 973-347-1958 ext. 213  
Email: [email protected]
Web: http://www.dolcas-biotech.com

SOURCE DolCas Biotech, LLC